Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 29 Apr 2019
Price : $35 *
At a glance
- Drugs Entrectinib (Primary)
- Indications Cancer; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Ignyta; Roche
- 24 Apr 2019 Status changed from suspended to completed.
- 09 May 2018 Status changed from recruiting to suspended.
- 04 Mar 2017 New trial record